Tarsus Pharmaceuticals, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Tarsus reported Q3 2026 XDEMVY net product sales of $194.6M (64% YoY growth), surpassing 1M bottles dispensed and $1B cumulative sales since launch. The company acquired iRenix Medical (IRX-101, ocular antiseptic) and Alkeus Pharmaceuticals (gildeuretinol, Stargardt disease), recording $632.2M in acquired IPR&D write-offs ($81.0M iRenix, $551.2M Alkeus). Q3 net loss was $668.3M (vs. $12.6M prior year), driven primarily by acquisition-related IPR&D charges. Cash position declined to $309.6M from $344.3M (Dec 31, 2025). Appointed Neera Clase as Chief Commercial Officer.
Why this rating
XDEMVY blockbuster trajectory ($1B in 3 years) is game-changing for a $1.7B market-cap company (58% of size). Acquisitions add material pipeline depth. IPR&D charges are non-cash but reduce equity. Near-term profitability delayed, but revenue momentum and pipeline expansion are transformational.
Price action (we called it positive)
before filing · preread $72.64 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.